Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Open accessThe DOI matches its Crossref record; 27 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Alzheimer's disease is characterized by amyloid-beta plaques, neurofibrillary tangles, gliosis, and neuronal loss. Solanezumab, a humanized monoclonal antibody, preferentially binds soluble forms of amyloid and in preclinical studies promoted its clearance from the brain. METHODS: In two phase 3, double-blind trials (EXPEDITION 1 and EXPEDITION 2), we randomly assigned 1012 and 1040 patients, respectively, with mild-to-moderate Alzheimer's disease to receive placebo or solanezumab (administered intravenously at a dose of 400 mg) every 4 weeks for 18 months. The primary outcomes were the changes from baseline to week 80 in scores on the 11-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog11; range, 0 to 70, with higher scores indicating greater cognitive impairment) and the Alzheimer's Disease Cooperative Study-Activities of Daily Living scale (ADCS-ADL; range, 0 to 78, with lower scores indicating worse functioning). After analysis of data from EXPEDITION 1, the primary outcome for EXPEDITION 2 was revised to the change in scores on the 14-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog14; range, 0 to 90, with higher scores indicating greater impairment), in patients with mild Alzheimer's disease. RESULTS: Neither study showed significant improvement in the primary outcomes. The modeled difference between groups (solanezumab group minus placebo group) in the change from baseline was -0.8 points for the ADAS-cog11 score (95% confidence interval [CI], -2.1 to 0.5; P=0.24) and -0.4 points for the ADCS-ADL score (95% CI, -2.3 to 1.4; P=0.64) in EXPEDITION 1 and -1.3 points (95% CI, -2.5 to 0.3; P=0.06) and 1.6 points (95% CI, -0.2 to 3.3; P=0.08), respectively, in EXPEDITION 2. Between-group differences in the changes in the ADAS-cog14 score were -1.7 points in patients with mild Alzheimer's disease (95% CI, -3.5 to 0.1; P=0.06) and -1.5 in patients with moderate Alzheimer's disease (95% CI, -4.1 to 1.1; P=0.26). In the combined safety data set, the incidence of amyloid-related imaging abnormalities with edema or hemorrhage was 0.9% with solanezumab and 0.4% with placebo for edema (P=0.27) and 4.9% and 5.6%, respectively, for hemorrhage (P=0.49). CONCLUSIONS: Solanezumab, a humanized monoclonal antibody that binds amyloid, failed to improve cognition or functional ability. (Funded by Eli Lilly; EXPEDITION 1 and 2 ClinicalTrials.gov numbers, NCT00905372 and NCT00904683.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Florbetapir PET analysis did not show a reduction in brain amyloid deposits with solanezumab [45, 46].”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [45]
In the citing paper
“bapineuzumab and solanezumab showed no cognitive improvement in Phase 3 trials [46,47]”
From Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions (2026) · cites this paper as [46]
In the citing paper
“Clinical trials often fail to deliver benefits.”
From Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions (2026) · cites this paper as [46]
In the citing paper
“and a similar proportion has normal amyloid PET or CSF Aβ42 studies [53–62].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [57]
In the citing paper
“While recent clinical trials of anti‐amyloid therapies, such as donanemab and lecanemab, 2 , 3 have shown promising results, the failures of earlier treatments like solanezumab and bapineuzumab indicate that targeting a single AD‐specific pathological process is insufficient to mitigate cognitive decline. 4 , 5 , 6”
From White matter hyperintensity modulates the amyloid‐tau‐cognition association and anti‐amyloid treatment efficacy in asymptomatic older adults (2025) · cites this paper as [6]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
Sheikh (1986) · doi:10.1300/j018v05n01_09 · Cited by 7,236
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Assessing Quality of Life in Older Adults With Cognitive Impairment
Logsdon, R. G., Gibbons, L. E., McCurry, S. M., & Teri, L. (2002) · Psychosomatic Medicine · doi:10.1097/00006842-200205000-00016 · Cited by 1,381
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
Self-citationAn Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimerʼs Disease
Galasko, D., Bennett, D., Sano, M., Ernesto, C., Thomas, R., Grundman, M., & Ferris, S. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00005 · Cited by 1,194
Self-citationO’Bryant, S. E. (2008) · Archives of Neurology · doi:10.1001/archneur.65.8.1091 · Cited by 884
Research works printed but not linked: 2
- Wimo A, Wetterholm AL, Mastey V, Winbald B. Evaluations of resource utilization and caregiver time in anti-dementia drug trials- a quantitative battery. In: Wimo A, Jonsson B, Karlsson G, Winbald B, eds. The health economics of dementia. London: John Wiley, 1998:465-99.
- Kind P. 1996. The EuroQol instrument: an index of health-related quality of life. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven, 1996:191-201.
Cited by
Items 501–600 of 1,006
Beck, T. N., Nicolas, E., Kopp, M. C., & Golemis, E. A. (2014) · Oncoscience · doi:10.18632/oncoscience.64 · Cited by 50
“There are currently no effective treatment strategies for AD, and the disease typically leads to death within 3 to 9 years [15, 17, 18].”
BackgroundThe emerging role of PET imaging in dementia
Iaccarino, L., Sala, A., Caminiti, S. P., & Perani, D. (2017) · F1000Research · doi:10.12688/f1000research.11603.1 · Cited by 50
How technology is reshaping cognitive assessment: Lessons from the Framingham Heart Study.
Au, R., Piers, R. J., & Devine, S. (2017) · Neuropsychology · doi:10.1037/neu0000411 · Cited by 49
“Further, the continued failure of clinical trial studies reflects, in part, treatment interventions that are too late to reverse course of the disease (Sperling, Karlawish, & Johnson, 2013; Salloway et al., 2014; Doody et al., 2014; Belluck, 2016; Taylor, 2017).”
BackgroundModeling neurological disorders using brain organoids
Zhang, D. Y., Song, H., & Ming, G. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.05.026 · Cited by 54
Mukherjee, S., Perez, K. A., Lago, L., Klatt, S., McLean, C., Birchall, I. E., Barnham, K. J., Masters, C. L., & Roberts, B. R. (2021) · Brain Communications · doi:10.1093/braincomms/fcab028 · Cited by 54
Bayes analysis supports null hypothesis of anti‐amyloid beta therapy in Alzheimer's disease
Richard, E., den Brok, M. G. H. E., & van Gool, W. A. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12379 · Cited by 50
“not sufficiently well-defined, the follow-up too short, or the outcome parameters too insensitive to detect subtle effects; or (3) the true effect of a therapeutic approach is indeed absent.”
BackgroundThe evolving landscape of Alzheimer’s disease therapy: From Aβ to tau
Courade, J., Zetterberg, H., Höglinger, G. U., & Dewachter, I. (2025) · Cell · doi:10.1016/j.cell.2025.11.033 · Cited by 68
Alzheimer’s Disease, Anesthesia, and Surgery: A Clinically Focused Review
Berger, M., Burke, J. R., Eckenhoff, R. G., & Mathew, J. P. (2014) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2014.04.014 · Cited by 53
Immunotherapy targeting pyroglutamate-3 Aβ: prospects and challenges
Cynis, H., Frost, J. L., Crehan, H., & Lemere, C. A. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0115-2 · Cited by 49
Frequency-dependent exacerbation of Alzheimer’s disease neuropathophysiology
Kastanenka, K. V., Calvo-Rodríguez, M., Hou, S. S., Zhou, H., Takeda, S., Arbel‐Ornath, M., Lariviere, A., Lee, Y. F., Kim, A., Hawkes, J. M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-44964-z · Cited by 49
Future Therapeutics in Alzheimer’s Disease: Development Status of BACE Inhibitors
Evin, G. M. (2016) · BioDrugs · doi:10.1007/s40259-016-0168-3 · Cited by 56
Deming, Y., Li, Z., Benitez, B. A., & Cruchaga, C. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1486823 · Cited by 48
Delayed‐start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years
Liu‐Seifert, H., Siemers, E., Holdridge, K. C., Andersen, S. W., Lipkovich, I., Carlson, C., Sethuraman, G., Hoog, S., Hayduk, R., Doody, R., et al. (2015) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2015.06.006 · Cited by 48
Self-citationNeuroimaging biomarkers in Alzheimer’s disease and other dementias
Villemagne, V. L., & Chételat, G. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.01.004 · Cited by 60
Amanatkar, H. R., Papagiannopoulos, B., & Grossberg, G. T. (2016) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2016.1194203 · Cited by 50
Advances in Brain Amyloid Imaging
Krishnadas, N., Villemagne, V. L., Doré, V., & Rowe, C. C. (2021) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2020.12.005 · Cited by 47
What lessons can be learned from failed Alzheimer’s disease trials?
Toyn, J. H. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1034690 · Cited by 53
DNA repair deficiency and senescence in concussed professional athletes involved in contact sports
Schwab, N., Grenier, K., & Hazrati, L.-N. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0822-3 · Cited by 47
NPT088 reduces both amyloid‐β and tau pathologies in transgenic mice
Levenson, J. M., Schroeter, S., Carroll, J. C., Cullen, V., Asp, E., Proschitsky, M., Chung, C. H. ‐., Gilead, S., Nadeem, M., Dodiya, H. B., et al. (2016) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.06.004 · Cited by 47
Lathuilière, A., Mach, N., & Schneider, B. L. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160510578 · Cited by 53
Liu, Y.-H., Bu, X.-L., Liang, C.-R., Wang, Y.-R., Zhang, T., Jiao, S.-S., Zeng, F., Yao, X.-Q., Zhou, H.-D., Deng, J., et al. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0379-4 · Cited by 47
Modeling Prion-Like Processing of Tau Protein in Alzheimer’s Disease for Pharmaceutical Development
Wischik, C. M., Schelter, B. O., Wischik, D., Storey, J. M. D., & Harrington, C. R. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170727 · Cited by 54
“In patients taking the same doses of LMTM as add-on to approved anti-dementia treatments, the decline was indistinguishable from controls as randomized or from placebo controls in recently reported studies [54, 55].”
ResultCurrent Perspectives regarding Stem Cell-Based Therapy for Alzheimer’s Disease
Kwak, K.-A., Lee, S., Yang, J.-Y., & Park, Y. (2018) · Stem Cells International · doi:10.1155/2018/6392986 · Cited by 54
Torshizi, A. D., & Wang, K. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.05.015 · Cited by 52
Therapeutic Strategies to Reduce the Toxicity of Misfolded Protein Oligomers
Kreiser, R. P., Wright, A. K., Block, N. R., Hollows, J. E., Nguyen, L. T., LeForte, K., Mannini, B., Vendruscolo, M., & Limbocker, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228651 · Cited by 51
“Solanezumab Antibody Aβ aggregates, in particular soluble forms Binds soluble forms of Aβ and promotes its clearance from the brain in pre-clinical models [68,209]; did not meet endpoints in two Phase 3 trails, with one Phase 3 trial currently ongoing”
BackgroundBack to the future: Alzheimer's disease heterogeneity revisited
Au, R., Piers, R. J., & Lancashire, L. (2015) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2015.05.006 · Cited by 45
Lathuilière, A., Laversenne, V., Astolfo, A., Kopetzki, E., Jacobsen, H., Stampanoni, M., Bohrmann, B., Schneider, B. L., & Aebischer, P. (2016) · Brain · doi:10.1093/brain/aww036 · Cited by 46
Beneficial effects of white wine polyphenols-enriched diet on Alzheimer’s disease-like pathology
Mendes, D., Oliveira, M. M., Moreira, P. I., Coutinho, J., Nunes, F. M., Pereira, D. M., Valentão, P., Andrade, P. B., & Videira, R. A. (2018) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2018.02.001 · Cited by 55
Personality and Incident Alzheimer’s Disease: Theory, Evidence, and Future Directions
Segerstrom, S. C. (2018) · The Journals of Gerontology Series B · doi:10.1093/geronb/gby063 · Cited by 54
Using sigma-ligands as part of a multi-receptor approach to target diseases of the brain
Brimson, J. M., Brimson, S., Chomchoei, C., & Tencomnao, T. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1805435 · Cited by 46
Slater, C. L., & Wang, Q. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.397 · Cited by 50
Irwin, R. W., Solinsky, C. M., Loya, C. M., Salituro, F. G., Rodgers, K. E., Bauer, G., Rogawski, M. A., & Brinton, R. D. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128313 · Cited by 50
Predicting Reduction of Cerebrospinal Fluid β-Amyloid 42 in Cognitively Healthy Controls
Mattsson, N., Insel, P. S., Donohue, M., Jagust, W., Sperling, R., Aisen, P., & Weiner, M. W. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.4530 · Cited by 45
Self-citationAyton, S., & Bush, A. I. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101212 · Cited by 45
Degenhardt, E. K., Witte, M. M., Case, M. G., Yu, P., Henley, D. B., Hochstetler, H. M., D’Souza, D. N., & Trzepacz, P. T. (2016) · Psychosomatics · doi:10.1016/j.psym.2015.12.002 · Cited by 48
Harnessing Immunoproteostasis to Treat Neurodegenerative Disorders
Golde, T. E. (2019) · Neuron · doi:10.1016/j.neuron.2019.02.027 · Cited by 45
Global Trends in Alzheimer Disease Clinical Development: Increasing the Probability of Success
Sugino, H., Watanabe, A., Amada, N., Yamamoto, M., Ohgi, Y., Kostic, D., & Sanchez, R. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.07.006 · Cited by 48
Accelerating rates of cognitive decline and imaging markers associated with β-amyloid pathology
Insel, P. S., Mattsson, N., Mackin, R. S., Schöll, M., Nosheny, R. L., Tosun, D., Donohue, M. C., Aisen, P. S., Jagust, W. J., Weiner, M. W., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002683 · Cited by 45
Self-citationENDPOINTS FOR PRE-DEMENTIA AD TRIALS: A REPORT FROM THE EU/US/CTAD TASK FORCE
Vellas, B., Bateman, R., Blennow, K., Frisoni, G., Johnson, K., Katz, R., Langbaum, J., Marson, D., Sperling, R., Wessels, A., et al. (2015) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2015.55 · Cited by 44
Self-citationKwakowsky, A., Guzmán, B. C., Govindpani, K., Waldvogel, H. J., & Faull, R. L. M. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.235240 · Cited by 49
Katsinelos, T., Tuck, B. J., Mukadam, A. S., & McEwan, W. A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01139 · Cited by 48
“Consistent with a transfer to periphery, both antibodies, as well as a monomer-binding monoclonal antibody, m266 which was given to mice, increased the serum concentration of Aβ (125, 127, 128).”
BackgroundMultidomain intervention and/or omega‐3 in nondemented elderly subjects according to amyloid status
Delrieu, J., Payoux, P., Carrié, I., Cantet, C., Weiner, M., Vellas, B., & Andrieu, S. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.07.008 · Cited by 45
“The negative results of bapineuzumab [2] and solanezumab [3] phase III trials were an important methodological turning point in AD therapeutic trials.”
BackgroundSelf-citationLiu, Y., Wang, J., Li, Q., Fowler, C. J., Zeng, F., Deng, J., Xu, Z., Zhou, H., Doecke, J. D., Villemagne, V. L., et al. (2021) · Science Advances · doi:10.1126/sciadv.abb0457 · Cited by 53
Effect of active A β immunotherapy on neurons in human Alzheimer's disease
Paquet, C., Amin, J., Mouton‐Liger, F., Nasser, M., Love, S., Gray, F., Pickering, R. M., Nicoll, J. A., Holmes, C., Hugon, J., et al. (2015) · The Journal of Pathology · doi:10.1002/path.4491 · Cited by 44
Comparing the efficacy and neuroinflammatory potential of three anti-abeta antibodies
Fuller, J. P., Stavenhagen, J. B., Christensen, S., Kartberg, F., Glennie, M. J., & Teeling, J. L. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1484-2 · Cited by 44
Targeting Thrombin: An Inflammatory Neurotoxin in Alzheimer's Disease
Grammas, P., & Martinez, J. M. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-141557 · Cited by 43
Liu-Seifert, H., Andersen, S. W., Lipkovich, I., Holdridge, K. C., & Siemers, E. (2015) · PLOS ONE · doi:10.1371/journal.pone.0119632 · Cited by 44
Self-citationDeak, F., Freeman, W. M., Ungvari, Z., Csiszar, A., & Sonntag, W. E. (2016) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glv206 · Cited by 44
Challenges, solutions, and recommendations for Alzheimer's disease combination therapy
Hendrix, J. A., Bateman, R. J., Brashear, H. R., Duggan, C., Carrillo, M. C., Bain, L. J., DeMattos, R., Katz, R. G., Ostrowitzki, S., Siemers, E., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.007 · Cited by 44
Self-citationArnerić, S. P., Batrla-Utermann, R., Beckett, L., Bittner, T., Blennow, K., Carter, L., Dean, R., Engelborghs, S., Genius, J., Gordon, M. F., et al. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160573 · Cited by 44
Modulation of innate immunity of patients with Alzheimer's disease by omega‐3 fatty acids
Fiala, M., Kooij, G., Wagner, K., Hammock, B., & Pellegrini, M. (2017) · The FASEB Journal · doi:10.1096/fj.201700065r · Cited by 44
Recent advancements toward therapeutic vaccines against Alzheimer’s disease
Herline, K., Drummond, E., & Wisniewski, T. (2018) · Expert Review of Vaccines · doi:10.1080/14760584.2018.1500905 · Cited by 44
“Disappointingly, Phase III trial results (EXPEDITION-1 and -2 trials) showed no overall significant cognitive improvement in the treatment group as measured by ADAS-Cog11 and ADCS-ADL scores [44].”
ResultThe application of positron emission tomography (PET) imaging in CNS drug development
Suridjan, I., Comley, R. A., & Rabiner, E. A. (2018) · Brain Imaging and Behavior · doi:10.1007/s11682-018-9967-0 · Cited by 45
Alzheimer’s Disease: Drug Discovery
(2020) · Exon Publications eBooks · doi:10.36255/exonpublications.alzheimersdisease.2020 · Cited by 44
The PKR/P38/RIPK1 Signaling Pathway as a Therapeutic Target in Alzheimer’s Disease
Hugon, J., & Paquet, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063136 · Cited by 45
Monoclonal Antibody Therapy in Alzheimer’s Disease
Neațu, M., Covaliu, A., Ioniță, I., Jugurt, A., Davidescu, E. I., & Popescu, B. O. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics16010060 · Cited by 48
“Even so, both studies failed to demonstrate the significant efficacy of solanezumab in slowing cognitive deterioration, and the primary objectives of the trial were not achieved [116–119].”
BackgroundMethodResultInfluentialMorphological and Molecular Profiling of Amyloid-β Species in Alzheimer’s Pathogenesis
Almeida, Z. L., Vaz, D. C., & Brito, R. M. M. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04543-4 · Cited by 52
Alzheimer's disease and other dementias: advances in 2014
Bateman, R. J. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70301-1 · Cited by 43
Gault, L. M., Lenz, R. A., Ritchie, C. W., Meier, A., Othman, A. A., Tang, Q., Berry, S., Pritchett, Y., & Robieson, W. Z. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0210-1 · Cited by 43
“Based on neuropathological analysis of patients meeting diagnostic criteria for AD [30, 31] and on recent clinical trial results showing that approximately 30 % of subjects selected with these criteria have negative positron emission tomography scans for amyloid [32, 33], we expect that some subjects in this trial wou…”
BackgroundVaccination strategies in tauopathies and synucleinopathies
Braczynski, A. K., Schulz, J. B., & Bach, J. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14207 · Cited by 45
Griffith, C. M., Macklin, L. N., Cai, Y., Sharp, A. A., Yan, X.-X., Reagan, L. P., Strader, A. D., Rose, G. M., & Patrylo, P. R. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-180707 · Cited by 43
A new dawn of preventing dementia by preventing cerebrovascular diseases
Pan, Y., Li, H., Wardlaw, J. M., & Wang, Y. (2020) · BMJ · doi:10.1136/bmj.m3692 · Cited by 37
Aggregation Mechanisms and Molecular Structures of Amyloid‐β in Alzheimer's Disease
Niu, Z., Gui, X., Feng, S., & Reif, B. (2024) · Chemistry - A European Journal · doi:10.1002/chem.202400277 · Cited by 53
The past, present, and future of disease-modifying therapies for Alzheimer’s disease
Suzuki, K., Iwata, A., & Iwatsubo, T. (2017) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.93.048 · Cited by 48
Self-citationHu, X., Teunissen, C. E., Spottke, A. E., Heneka, M. T., Düzel, E., Peters, O., Li, S., Priller, J., Büerger, K., Teipel, S. J., et al. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.09.002 · Cited by 49
“Alzheimer’s disease (AD) is a worldwide challenge due to the rapidly increasing number of patients, the associated financial and social burden, and the still lacking treatment to slow disease progression [1,2].”
BackgroundFujimoto, K., Matsuoka, E., Asada, N., Tadano, G., Yamamoto, T., Nakahara, K., Fuchino, K., Ito, H., Kanegawa, N., Moechars, D., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00309 · Cited by 47
Corsetti, V., Borreca, A., Latina, V., Giacovazzo, G., Pignataro, A., Krashia, P., Natale, F., Cocco, S., Rinaudo, M., Malerba, F., et al. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa039 · Cited by 42
Denny, A., Streitz, M. L., Stock, K., Balls‐Berry, J. E., Barnes, L. L., Byrd, G. S., Croff, R. L., Gao, S., Glover, C. M., Hendrie, H. C., et al. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12160 · Cited by 44
“The SHARP project created a culture of belonging in African American brain health research that addressed five questions: (1) How to create a culturally celebratory tone throughout the research? (2) How to create new opportunities? (3) How to serve community identified priorities? (4) What tool or service will continu…”
BackgroundPanza, F., Seripa, D., Lozupone, M., Solfrizzi, V., Imbimbo, B. P., Barulli, M. R., Tortelli, R., Capozzo, R., Bisceglia, P., Dimitri, A., et al. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1389885 · Cited by 41
Genome-Wide Association Studies of ARIA From the Aducanumab Phase 3 ENGAGE and EMERGE Studies
Loomis, S. J., Miller, R., Castrillo‐Viguera, C., Umans, K., Cheng, W., O'Gorman, J. T., Hughes, R. A., Haeberlein, S. B., & Whelan, C. D. (2023) · Neurology · doi:10.1212/wnl.0000000000207919 · Cited by 45
Sarazin, M., Lagarde, J., Haddad, I., de Souza, L. C., Bellier, B., Potier, M., Bottlaender, M., & Dorothée, G. (2024) · Nature Aging · doi:10.1038/s43587-024-00630-2 · Cited by 46
Ascher‐Svanum, H., Chen, Y.-F., Hake, A. M., Kahle‐Wrobleski, K., Schuster, D., Kendall, D. M., & Heine, R. J. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.01.002 · Cited by 48
Fiala, M., Terrando, N., & Dalli, J. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-150367 · Cited by 41
Qu, A., Huang, F., Li, A., Yang, H., Zhou, H., Long, J., & Shi, L. (2017) · Chemical Communications · doi:10.1039/c6cc07803f · Cited by 44
Wang, J., Lei, X., Cheng, X., Zhang, X., Liu, G., Cheng, J., Xu, Y., Ju, Z., Zhou, W., & Zhang, Y. (2016) · Alzheimer s Research & Therapy · doi:10.1186/s13195-016-0226-6 · Cited by 42
Neuroinflammation in Alzheimer’s Disease: Microglia, Molecular Participants and Therapeutic Choices
Wang, H., Shen, Y., Chuang, H., Chiu, C., Ye, Y., & Zhao, L. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190503151648 · Cited by 41
Trojan, E., Bryniarska, N., Leśkiewicz, M., Regulska, M., Chamera, K., Szuster-Głuszczak, M., Leopoldo, M., Lacivita, E., & Basta‐Kaim, A. (2019) · Current Neuropharmacology · doi:10.2174/1570159x17666191019170244 · Cited by 44
White matter changes from mild cognitive impairment to Alzheimer’s disease: a meta-analysis
Qin, L., Guo, Z., McClure, M. A., & Mu, Q. (2020) · Acta Neurologica Belgica · doi:10.1007/s13760-020-01322-5 · Cited by 46
Amyloid-β and α-Synuclein Immunotherapy: From Experimental Studies to Clinical Trials
Nimmo, J., Kelly, L., Verma, A. K., Carare, R. O., Nicoll, J. A. R., & Dodart, J. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.733857 · Cited by 45
Zhang, Q., Zhao, W., Hou, Y., Song, X., Yu, H., Tan, J., Zhou, Y., & Zhang, H. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14132 · Cited by 40
Schwarz, A. J., Sundell, K. L., Charil, A., Case, M. G., Jaeger, R. K., Scott, D., Bracoud, L., Oh, J., Suhy, J., Pontecorvo, M. J., et al. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.05.007 · Cited by 40
“Initial phase 3, double-blind clinical trials of solanezumab, at a dose of 400 mg every 4 weeks for 76 weeks, in patients with clinically defined mild-to-moderate (baseline MiniMental State Examination [MMSE] score 16-26) AD (EXPEDITION and EXPEDITION2) failed to show a treatment benefit for solanezumab [3].”
BackgroundMethodSelf-citationOlfactory deficit: a potential functional marker across the Alzheimer’s disease continuum
Liu, D., Lu, J., Wei, L., Yao, M., Yang, H., Lv, P., Wang, H., Zhu, Y., Zhu, Z., Zhang, X., et al. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1309482 · Cited by 56
Thai, C., Lim, Y. Y., Villemagne, V. L., Laws, S. M., Ames, D., Ellis, K. A., Rainey-Smith, S. R., Martins, R. N., Masters, C. L., Rowe, C. C., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0139082 · Cited by 40
Brookmeyer, R., Kawas, C. H., Abdallah, N., Paganini‐Hill, A., Kim, R. C., & Corrada, M. M. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.01.004 · Cited by 40
Ivanoiu, A., Pariente, J., Booth, K., Lobello, K., Luscan, G., Hua, L., Lucas, P., Styren, S., Yang, L., Li, D., et al. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0193-y · Cited by 39
Akamatsu, G., Ikari, Y., Ohnishi, A., Nishida, H., Aita, K., Sasaki, M., Yamamoto, Y., Sasaki, M., & Senda, M. (2016) · Physics in Medicine and Biology · doi:10.1088/0031-9155/61/15/5768 · Cited by 43
Fleisher, A., Joshi, A. D., Sundell, K. L., Chen, Y., Kollack‐Walker, S., Lu, M., Chen, S., Devous, M. D., Seibyl, J. P., MAREK, K. L., et al. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.02.009 · Cited by 41
“gov numbers: NCT00905372 and NCT00904683) [16].”
BackgroundResultInfluentialSelf-citationCifuentes, D., Poittevin, M., Bonnin, P., Ngkelo, A., Kubis, N., Merkulova‐Rainon, T., & Levy, B. I. (2017) · Hypertension · doi:10.1161/hypertensionaha.117.09742 · Cited by 43
Santangelo, R., Cecchetti, G., Bernasconi, M. P., Cardamone, R., Barbieri, A., Pinto, P., Passerini, G., Scomazzoni, F., Comı, G., & Magnani, G. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170186 · Cited by 46
Wessels, A. M., Dowsett, S. A., & Sims, J. R. (2018) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2018.2 · Cited by 39
“Solanezumab Doody 2014 (37) EXPEDTION 1 1012 16-26 11 80”
Wang, L., Liu, S., Xu, J., Watanabe, N., Mayo, K. H., Li, J., & Li, X. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15156 · Cited by 41
“Disappointingly, nearly all antibodies that were shown to be effective in vitro have suffered setbacks in clinical trials (Doody et al., 2014; Gilman et al., 2005; Orgogozo et al., 2003; Salloway et al., 2014).”
BackgroundTherapeutic antibodies – natural and pathological barriers and strategies to overcome them
Ojaimi, Y. A., Blin, T., Lamamy, J., Gracia, M., Pitiot, A., Denevault-Sabourin, C., Joubert, N., Pouget, J., Gouilleux-Gruart, V., Heuzé-Vourc'h, N., et al. (2021) · Pharmacology and Therapeutics · doi:10.1016/j.pharmthera.2021.108022 · Cited by 34
Anti-dementia medications: current prescriptions in clinical practice and new agents in progress
Stella, F., Radanovic, M., Canineu, P. R., de Paula, V. D. J. R., & Forlenza, O. V. (2015) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098615592116 · Cited by 46
Berlyand, Y., Weintraub, D. A., Xie, S. X., Mellis, I. A., Doshi, J. J., Rick, J. H., McBride, J. D., Davatzikos, C. A., Shaw, L. M. J., Hurtig, H. I., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147319 · Cited by 41
Tip-enhanced Raman spectroscopy of amyloid β at neuronal spines
Tabatabaei, M., Caetano, F. A., Pashee, F., Ferguson, S. S. G., & Lagugné‐Labarthet, F. (2017) · The Analyst · doi:10.1039/c7an00744b · Cited by 39
Clinical Evaluation of Amyloid-Related Imaging Abnormalities in Bapineuzumab Phase III Studies
Brashear, H. R., Ketter, N., Bogert, J., Di, J., Salloway, S. P., & Sperling, R. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-180675 · Cited by 39
Alleviation of symptoms of Alzheimer's disease by diminishing Aβ neurotoxicity and neuroinflammation
Yang, T., Zhu, Z., Yin, E., Wang, Y., Zhang, C., Yuan, H., Zhang, H., Jin, S., Guo, Z., & Wang, X. (2019) · Chemical Science · doi:10.1039/c9sc03042e · Cited by 39
Bradfield, N. I., & Ames, D. J. (2019) · BJPsych Bulletin · doi:10.1192/bjb.2019.77 · Cited by 45
ApoE mimetic improves pathology and memory in a model of Alzheimer’s disease
Krishnamurthy, K., Cantillana, V., Wang, H., Sullivan, P. M., Kolls, B. J., Ge, X., Lin, Y., Mace, B., & Laskowitz, D. T. (2020) · Brain Research · doi:10.1016/j.brainres.2020.146685 · Cited by 39
Nanoliposomes as a Therapeutic Tool for Alzheimer’s Disease
Ordóñez-Gutiérrez, L., & Wandosell, F. (2020) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2020.00020 · Cited by 32
Metadata
- Authors
- Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., & Mohs, R.
- Affiliations
- Baylor College of Medicine (US)
- University of California San Diego (US)
- Indiana University (US)
- The University of Tokyo (JP)
- Centre Hospitalier Universitaire de Toulouse (FR)
- University of Pennsylvania (US)
- University of Rochester Medicine (US)
- Eli Lilly (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-01-23
- Volume
- 370
- Issue
- 4
- Pages
- 311-321
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2015484447
- Cited by
- 1,668
- References
- 28
- Citations by year
- 2026: 63 · 2025: 84 · 2024: 110 · 2023: 116 · 2022: 101 · 2021: 103 · 2020: 154 · 2019: 145 · 2018: 155 · 2017: 163 · 2016: 183 · 2015: 178 · 2014: 111
- FWCI
- 140.73
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- solanezumab, Alzheimer's disease, amyloid-beta, anti-amyloid monoclonal antibodies, cognitive impairment, activities of daily living, mild to moderate Alzheimer's disease, placebo response
- MeSH terms
- Activities of Daily Living, Aged, Aged, 80 and over, Alzheimer Disease, Apolipoproteins E, Cognition, Double-Blind Method, Female, Humans, Male, Neuropsychological Tests, Severity of Illness Index, Biomarkers, Amyloid beta-Peptides, tau Proteins, Treatment Failure, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.